Shire is to acquire Californian-based biopharmaceutical company, SARcode Bioscience Inc, with an upfront payment of US $160 million. Shire is hoping to use this acquisition to build on its ...

Underlining its ambitions in ophthalmology, Shire plc is acquiring SARcode Bioscience Inc. for $160 million up front, plus additional, undisclosed milestones based on the clinical, regulatory and ...

Lead candidate selected for Phase I studies will be developed in ophthalmology. SARcode bought Sunesis Pharmaceuticals’ intellectual property and assets related to the LFA-1 inhibitor program ...

Privately held SARcode Bioscience Inc. has enrolled the first patient in OPUS-1, its pivotal Phase III trial of topical SAR 1118 ophthalmic solution. OPUS-1 will study the safety and efficacy of SAR ...

Don Taylor joined InkSure Techologies in 2006 to lead global strategic market development initiatives. Prior to joining the company, he served as Vice President of Marketing at Dedicated Micros Inc., ...

Shire of Dublin, Ireland, is buying Brisbane, Calif.-based biopharmaceutical startup SARcode Bioscience for $160 million upfront, "plus additional undisclosed payments upon achievement of certain ...

SARcode’s experimental treatment Lifitegrast for dry eye disease may reach the market in the U.S. as early as 2016, Dublin-based Shire said today in a statement. Shire will pay $160 million to ...

The acquisition of SARcode, a privately-held, venture-backed biopharmaceutical in Brisbane, Calif. founded in 2006, comes just a little over a week after Shire acquired Premacure, a Swedish ...

With a pack of Genentech Inc. veterans, SARcode has moved its drug, called lifitegrast, from South San Francisco's Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) into the two studies, including one ...

Shire of Dublin, Ireland, is buying Brisbane, Calif.-based biopharmaceutical startup SARcode Bioscience for $160 million upfront, "plus additional undisclosed payments upon achievement of certain ...

Co announces it has earned a milestone payment from SARcode Corporation for progress made by SARcode in the preclinical development of a novel LFA-1 inhibitor candidate. The milestone payment, a ...